RxDoctor Payments Data

Karen Roberts

Nurse Practitioner · Rome, GANPI 1689676041

Payments from drug & device makers

$3,908in general payments, 2019–2025

Across 259 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Novartis$614
  • Amgen$185
  • Pfizer$178
  • E.r. Squibb & Sons, L.L.C.$167
  • Merck$143
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,895100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,908 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$59,553
Medicare patients
402
Services billed
812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan187$178,089
EliquisApixaban143$135,198
XareltoRivaroxaban152$114,315
JardianceEmpagliflozin57$43,894
FarxigaDapagliflozin Propanediol51$37,666
BrilintaTicagrelor47$29,404
Repatha SureclickEvolocumab15$13,457
Ranolazine ErRanolazine139$9,995
ClopidogrelClopidogrel Bisulfate180$2,135
Isosorbide Mononitrate ErIsosorbide Mononitrate150$1,816
Metoprolol Tartrate297$1,595
Hydralazine Hcl83$1,464
Metoprolol Succinate125$1,427
Atorvastatin Calcium144$1,377
Flecainide Acetate19$1,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$614$178,089187 claims
PfizerEliquis$178$135,198143 claims
Johnson & JohnsonXarelto$1,592$114,315152 claims
AstraZenecaFarxiga, Brilinta$114$67,06998 claims
Boehringer IngelheimJardiance$53$43,89457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →